ORY-2001

An LSD1 and MAO-B inhibitor (IC50s = 0.101 and 0.073 µM, respectively), selective for LSD1 and MAO-B over MAO-A (IC50 = 5.47 µM) and LSD2, SMOX, and LAAO at 10 µM, as well as a panel of 19 additional epigenetic targets and a panel of 92 receptors, ion channels, enzymes, and transporters at 10 µM, induces differentiation in THP-1 cells (EC50 = 21 nM), reverses memory deficits in the SAMP8 mouse model of accelerated aging and Alzheimer's disease from 0.11-3.2 mg/kg, reduces aggression in SAMP8 mice at 0.96 mg/kg, decreases disease severity in a mouse model of EAE from 0.05-1 mg/kg